Fleur Marcia Ferguson - Related publications

Affiliations: 
Harvard Medical School/Dana-Farber Cancer Institute, Boston, MA, United States 
Area:
Chemical Biology
NOTE: We are testing a new system for identifying relevant work based on semantic analysis that identifies similarities between recently published papers and the current author's publications. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches.
50 most relevant papers in past 60 days:
Year Citation  Score
2021 Zain R, Vihinen M. Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors. Frontiers in Immunology. 12: 694853. PMID 34349760 DOI: 10.3389/fimmu.2021.694853   
2021 Soltan OM, Shoman ME, Abdel-Aziz SA, Narumi A, Konno H, Abdel-Aziz M. Molecular hybrids: A five-year survey on structures of multiple targeted hybrids of protein kinase inhibitors for cancer therapy. European Journal of Medicinal Chemistry. 225: 113768. PMID 34450497 DOI: 10.1016/j.ejmech.2021.113768   
2021 Chen SJ, Bi YH, Zhang LH. Systematic analysis of the potential off-target activities of osimertinib by computational target fishing. Anti-Cancer Drugs. PMID 34459459 DOI: 10.1097/CAD.0000000000001229   
2021 Preynat-Seauve O, Nguyen EB, Westermaier Y, Héritier M, Tardy S, Cambet Y, Feyeux M, Caillon A, Scapozza L, Krause KH. Novel Mechanism for an Old Drug: Phenazopyridine is a Kinase Inhibitor Affecting Autophagy and Cellular Differentiation. Frontiers in Pharmacology. 12: 664608. PMID 34421588 DOI: 10.3389/fphar.2021.664608   
2021 Kang M, Kim C, Leem J, Kim YH, Kwon YJ, Yoon YN, Chae CH, Ahn J, Jung KY, Oh JS, Kim JS. Discovery and Characterization of a Novel MASTL Inhibitor MKI-2 Targeting MASTL-PP2A in Breast Cancer Cells and Oocytes. Pharmaceuticals (Basel, Switzerland). 14. PMID 34358073 DOI: 10.3390/ph14070647   
2021 Attwood MM, Fabbro D, Sokolov AV, Knapp S, Schiöth HB. Trends in kinase drug discovery: targets, indications and inhibitor design. Nature Reviews. Drug Discovery. PMID 34354255 DOI: 10.1038/s41573-021-00252-y   
2021 Asati V, Anant A, Patel P, Kaur K, Gupta GD. Pyrazolopyrimidines as anticancer agents: A review on structural and target-based approaches. European Journal of Medicinal Chemistry. 225: 113781. PMID 34438126 DOI: 10.1016/j.ejmech.2021.113781   
2021 Drewry DH, Annor-Gyamfi JK, Wells CI, Pickett JE, Dederer V, Preuss F, Mathea S, Axtman AD. Identification of Pyrimidine-Based Lead Compounds for Understudied Kinases Implicated in Driving Neurodegeneration. Journal of Medicinal Chemistry. PMID 34333981 DOI: 10.1021/acs.jmedchem.1c00440   
2021 Lorenz R, Wu J, Herberg FW, Taylor SS, Engh RA. Drugging the Undruggable: How Isoquinolines and PKA Initiated the Era of Designed Protein Kinase Inhibitor Therapeutics. Biochemistry. PMID 34370450 DOI: 10.1021/acs.biochem.1c00359   
2021 Xu C, Liu Y, Zhao G. The development of 3-substituted indolin-2-one derivatives as kinase inhibitors for cancer therapy. Current Medicinal Chemistry. PMID 34465277 DOI: 10.2174/0929867328666210831142311   
2021 Shen Z, Yan YH, Yang S, Zhu S, Yuan Y, Qiu Z, Jia H, Wang R, Li GB, Li H. ProfKin: A comprehensive web server for structure-based kinase profiling. European Journal of Medicinal Chemistry. 225: 113772. PMID 34411891 DOI: 10.1016/j.ejmech.2021.113772   
2021 Zheng F, Meng T, Jiang D, Sun J, Yao H, Zhu JJ, Min Q. Nano-mediator-effector cascade systems for amplified protein kinase activity imaging and phosphorylation-induced drug release in vivo. Angewandte Chemie (International Ed. in English). PMID 34322988 DOI: 10.1002/anie.202109108   
2021 Zheng F, Meng T, Jiang D, Sun J, Yao H, Zhu JJ, Min Q. Nano-mediator-effector cascade systems for amplified protein kinase activity imaging and phosphorylation-induced drug release in vivo. Angewandte Chemie (International Ed. in English). PMID 34322988 DOI: 10.1002/anie.202109108   
2021 Temps C, Lietha D, Webb ER, Li XF, Dawson JC, Muir M, Macleod KG, Valero T, Munro AF, Contreras-Montoya R, Luque-Ortega JR, Fraser C, Beetham H, Schoenherr C, Lopalco M, et al. A novel mode of inhibiting SRC improves drug efficacy and tolerability. Cancer Research. PMID 34417202 DOI: 10.1158/0008-5472.CAN-21-0613   
2021 Yun Y, Hong VS, Jeong S, Choo H, Kim S, Lee J. 2-Thioxothiazolidin-4-one Analogs as Pan-PIM Kinase Inhibitors. Chemical & Pharmaceutical Bulletin. 69: 854-861. PMID 34470949 DOI: 10.1248/cpb.c21-00264   
2021 Hallal M, Braga-Lagache S, Jankovic J, Simillion C, Bruggmann R, Uldry AC, Allam R, Heller M, Bonadies N. Inference of kinase-signaling networks in human myeloid cell line models by Phosphoproteomics using kinase activity enrichment analysis (KAEA). Bmc Cancer. 21: 789. PMID 34238254 DOI: 10.1186/s12885-021-08479-z   
2021 Serafim RAM, Elkins JM, Zuercher WJ, Laufer SA, Gehringer M. Chemical Probes for Understudied Kinases: Challenges and Opportunities. Journal of Medicinal Chemistry. PMID 34477374 DOI: 10.1021/acs.jmedchem.1c00980   
2021 Chu YH, Sadow PM. Kinase fusion-related thyroid carcinomas: distinct pathologic entities with evolving diagnostic implications. Diagnostic Histopathology (Oxford, England). 27: 252-262. PMID 34484420 DOI: 10.1016/j.mpdhp.2021.03.003   
2021 Quambusch L, Depta L, Landel I, Lubeck M, Kirschner T, Nabert J, Uhlenbrock N, Weisner J, Kostka M, Levy LM, Schultz-Fademrecht C, Glanemann F, Althoff K, Müller MP, Siveke JT, et al. Cellular model system to dissect the isoform-selectivity of Akt inhibitors. Nature Communications. 12: 5297. PMID 34489430 DOI: 10.1038/s41467-021-25512-8   
2021 Yu F, Cai M, Shao L, Zhang J. Targeting Protein Kinases Degradation by PROTACs. Frontiers in Chemistry. 9: 679120. PMID 34277564 DOI: 10.3389/fchem.2021.679120   
2021 Singh VJ, Sharma B, Chawla PA. Recent developments in mitogen activated protein kinase inhibitors as potential anticancer agents. Bioorganic Chemistry. 114: 105161. PMID 34328852 DOI: 10.1016/j.bioorg.2021.105161   
2021 Elkamhawy A, Ammar UM, Paik S, Abdellattif MH, Elsherbeny MH, Lee K, Roh EJ. Scaffold Repurposing of In-House Small Molecule Candidates Leads to Discovery of First-in-Class CDK-1/HER-2 Dual Inhibitors: In Vitro and In Silico Screening. Molecules (Basel, Switzerland). 26. PMID 34500757 DOI: 10.3390/molecules26175324   
2021 Fournier JCL, Evans JP, Zappacosta F, Thomas DA, Patel VK, White GV, Campos S, Tomkinson NCO. Acetylation of the Catalytic Lysine Inhibits Kinase Activity in PI3Kδ. Acs Chemical Biology. PMID 34397208 DOI: 10.1021/acschembio.1c00225   
2021 Ahmadu AA, Delehouzé C, Haruna A, Mustapha L, Lawal BA, Udobre A, Baratte B, Triscornia C, Autret A, Robert T, Bulinski JC, Rousselot M, Simoes Eugénio M, Dimanche-Boitrel MT, Petzer JP, et al. Betulin, a Newly Characterized Compound in Bark, Is a Multi-Target Protein Kinase Inhibitor. Molecules (Basel, Switzerland). 26. PMID 34361750 DOI: 10.3390/molecules26154599   
2021 Gautam V, Nimmanpipug P, Zain SM, Rahman NA, Lee VS. Molecular Dynamics Simulations in Designing DARPins as Phosphorylation-Specific Protein Binders of ERK2. Molecules (Basel, Switzerland). 26. PMID 34361694 DOI: 10.3390/molecules26154540   
2021 Marholz LJ, Federspiel JD, Suh H, Fernandez Ocana M. Highly Multiplexed Kinase Profiling in Spleen with Targeted Mass Spectrometry Reveals Kinome Plasticity across Species. Journal of Proteome Research. PMID 34319750 DOI: 10.1021/acs.jproteome.1c00199   
2021 Maldonado E, Rojas DA, Urbina F, Solari A. T. cruzi DNA polymerase beta (Tcpolβ) is phosphorylated in vitro by CK1, CK2 and TcAUK1 leading to the potentiation of its DNA synthesis activity. Plos Neglected Tropical Diseases. 15: e0009588. PMID 34260580 DOI: 10.1371/journal.pntd.0009588   
2021 Shu ST, Li WF, Smithgall TE. Visualization of Host Cell Kinase Activation by Viral Proteins Using GFP Fluorescence Complementation and Immunofluorescence Microscopy. Bio-Protocol. 11: e4068. PMID 34327265 DOI: 10.21769/BioProtoc.4068   
2021 Huang YM. Multi-scale computational investigations of ligand association pathways: Case of p38 MAP kinase and its inhibitors. Biophysical Journal. PMID 34453922 DOI: 10.1016/j.bpj.2021.08.026   
2021 Chan TY, Egbert CM, Maxson JE, Siddiqui A, Larsen LJ, Kohler K, Balasooriya ER, Pennington KL, Tsang TM, Frey M, Soderblom EJ, Geng H, Müschen M, Forostyan TV, Free S, et al. TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth. Nature Communications. 12: 5337. PMID 34504101 DOI: 10.1038/s41467-021-25622-3   
2021 Toman D, Jorda R, Ajani H, Kryštof V, Cankař P. Synthesis of 4-styrylpyrazoles and evaluation of their inhibitory effects on cyclin-dependent kinases. Medicinal Chemistry (Shariqah (United Arab Emirates)). PMID 34365958 DOI: 10.2174/1573406417666210806095710   
2021 Kong L, Zhang Q, Mao J, Cheng L, Shi X, Yu L, Hu J, Yang M, Li L, Liu B, Qian X. A dual-targeted molecular therapy of PP242 and cetuximab plays an anti-tumor effect through EGFR downstream signaling pathways in colorectal cancer. Journal of Gastrointestinal Oncology. 12: 1625-1642. PMID 34532116 DOI: 10.21037/jgo-21-467   
2021 Sanchez-Garrido J, Shenoy AR. Regulation and repurposing of nutrient sensing and autophagy in innate immunity. Autophagy. 17: 1571-1591. PMID 32627660 DOI: 10.1080/15548627.2020.1783119   
2021 Rho SB, Lee KW, Lee SH, Byun HJ, Kim BR, Lee CH. Novel Anti-Angiogenic and Anti-Tumour Activities of the N-Terminal Domain of NOEY2 via Binding to VEGFR-2 in Ovarian Cancer. Biomolecules & Therapeutics. 29: 506-518. PMID 34462379 DOI: 10.4062/biomolther.2021.121   
2021 Dong Y, Han H, Li Y, Guo L. [Roles of Histidine Kinases and Histidine Phosphatases in Cancer]. Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer. PMID 34455734 DOI: 10.3779/j.issn.1009-3419.2021.102.28   
2021 Kondo Y, Paul JW, Subramaniam S, Kuriyan J. New insights into Raf regulation from structural analyses. Current Opinion in Structural Biology. 71: 223-231. PMID 34454301 DOI: 10.1016/j.sbi.2021.07.005   
2021 Yeung W, Kwon A, Taujale R, Bunn C, Venkat A, Kannan N. Evolution of functional diversity in the holozoan tyrosine kinome. Molecular Biology and Evolution. PMID 34515793 DOI: 10.1093/molbev/msab272   
2021 Fu W, Wang E, Ke D, Yang H, Chen L, Shao J, Hu X, Xu L, Liu N, Hou T. Discovery of a Novel Mitogen-Activated Protein Kinase (FgGpmk1) Inhibitor for the Treatment of Fusarium Head Blight. Journal of Medicinal Chemistry. PMID 34519507 DOI: 10.1021/acs.jmedchem.1c01227   
2021 Karamafrooz A, Brennan J, Thomas DD, Parker LL. Integrated Phosphoproteomics for Identifying Substrates of Human Protein Kinase A () and Its Oncogenic Mutant 1. Journal of Proteome Research. PMID 34436901 DOI: 10.1021/acs.jproteome.1c00500   
2021 Qiu S, Liu Y, Li Q. A mechanism for localized dynamics-driven activation in Bruton's tyrosine kinase. Royal Society Open Science. 8: 210066. PMID 34457331 DOI: 10.1098/rsos.210066   
2021 Mustafa M, Abd El-Hafeez AA, Abdelhafeez DA, Abdelhamid D, Mostafa YA, Ghosh P, Hayallah AM, A Abuo-Rahma GE. FAK inhibitors as promising anticancer targets: present and future directions. Future Medicinal Chemistry. PMID 34340532 DOI: 10.4155/fmc-2021-0015   
2021 Jadaun KS, Sharma A, Siddiqui EM, Mehan S. Targeting abnormal PI3K/AKT/mTOR signaling in intracerebral hemorrhage: A systematic review on potential drug targets and influences of signaling modulators on other neurological disorders. Current Reviews in Clinical and Experimental Pharmacology. PMID 34455956 DOI: 10.2174/1574884716666210726110021   
2021 Park K, Haura EB, Leighl NB, Mitchell P, Shu CA, Girard N, Viteri S, Han JY, Kim SW, Lee CK, Sabari JK, Spira AI, Yang TY, Kim DW, Lee KH, et al. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2100662. PMID 34339292 DOI: 10.1200/JCO.21.00662   
2021 Che J, Dai X, Gao J, Sheng H, Zhan W, Lu Y, Li D, Gao Z, Jin Z, Chen B, Luo P, Yang B, Hu Y, He Q, Weng Q, et al. Discovery of -((3,4)-4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl-1-pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity. Journal of Medicinal Chemistry. PMID 34375113 DOI: 10.1021/acs.jmedchem.1c00815   
2021 Wei LY, Lin W, Leo BF, Kiew LV, Chang CC, Yuan CJ. Development of the Sensing Platform for Protein Tyrosine Kinase Activity. Biosensors. 11. PMID 34356711 DOI: 10.3390/bios11070240   
2021 Ma J, Ren Y, Zhang JN, Lin L, Zhang YL. [Analysis on targets of regulating Qi and activating blood based on activity spectrum of targets]. Zhongguo Zhong Yao Za Zhi = Zhongguo Zhongyao Zazhi = China Journal of Chinese Materia Medica. 46: 3970-3979. PMID 34472274 DOI: 10.19540/j.cnki.cjcmm.20210303.401   
2021 Dayal N, Řezníčková E, Hernandez DE, Peřina M, Torregrosa-Allen S, Elzey BD, Škerlová J, Ajani H, Djukic S, Vojáčková V, Lepšík M, Řezáčová P, Kryštof V, Jorda R, Sintim HO. 3-Pyrazolo[4,3-]quinoline-Based Kinase Inhibitors Inhibit the Proliferation of Acute Myeloid Leukemia Cells In Vivo. Journal of Medicinal Chemistry. PMID 34288692 DOI: 10.1021/acs.jmedchem.1c00330   
2021 Dayal N, Řezníčková E, Hernandez DE, Peřina M, Torregrosa-Allen S, Elzey BD, Škerlová J, Ajani H, Djukic S, Vojáčková V, Lepšík M, Řezáčová P, Kryštof V, Jorda R, Sintim HO. 3-Pyrazolo[4,3-]quinoline-Based Kinase Inhibitors Inhibit the Proliferation of Acute Myeloid Leukemia Cells In Vivo. Journal of Medicinal Chemistry. PMID 34288692 DOI: 10.1021/acs.jmedchem.1c00330   
2021 Woodall NB, Weinberg Z, Park J, Busch F, Johnson RS, Feldbauer MJ, Murphy M, Ahlrichs M, Yousif I, MacCoss MJ, Wysocki VH, El-Samad H, Baker D. De novo design of tyrosine and serine kinase-driven protein switches. Nature Structural & Molecular Biology. 28: 762-770. PMID 34518698 DOI: 10.1038/s41594-021-00649-8   
2021 Serafim RAM, Sorrell FJ, Berger BT, Collins RJ, Vasconcelos SNS, Massirer KB, Knapp S, Bennett J, Fedorov O, Patel H, Zuercher WJ, Elkins JM. Discovery of a Potent Dual SLK/STK10 Inhibitor Based on a Maleimide Scaffold. Journal of Medicinal Chemistry. PMID 34463505 DOI: 10.1021/acs.jmedchem.0c01579